Clinical trials: Gram-Negative Bacteria
Multi-antibiotic Resistance
Screening of Multidrug Resistant Bacteria, and the Clinical Implication for the Patient
The goal of this observational study is to evaluate the screening for multidrug resistant bacteria in patients admitted to hospitals in Scania.
- Trial name
- NCT06370299
- Testing
- (exposure of) MDR carriage
- Volunteers
- 10,000 people
- Sponsor
- Region Skane
Multi-antibiotic Resistance
Use of New Antibiotics in Sweden
Antibiotic resistance is a growing global health problem of great concern, especially multidrug-resistant Gram-negative bacteria. In recent years some new antibiotics targeting these bacteria have been developed.
- Trial name
- NCT05048693
- Where
- 7 sites in Sweden
- Volunteers
- 41 people
- Sponsor
- Uppsala University
Antibiotic Therapy
Evaluating a Novel Individualised Treatment Strategy for Carbapenem-Resistant Gram-Negative Bacteria Infections
Carbapenem-resistant (CR) Gram negative bacteria (GNB) - which are resistant to carbapenems (a last-line potent antibiotic with a high therapeutic index) - are also resistant to all other beta-lactam antibiotics.
- Trial name
- NCT04202861
- Testing
- In vitro antibiotic combination testing (iACT)
- Where
- Singapore
- Volunteers
- 594 people
- Sponsor
- Singapore General Hospital
Bloodstream Infection Multidrug-resistant Gram-negative Bacteria
Combating Multidrug-resistant Gram-negative Bacteria in Africa Through Diagnostic and Antimicrobial Stewardship
Antimicrobial resistance (AMR) is a major threat to public health and the well-being of humans, with high mortality rates of infections caused by MDR GNB.
- Trial name
- ComBac (NCT07820332)
- Testing
- Treatment according to AMR algorithm
- Volunteers
- 1,320 people
- Sponsor
- Universität des Saarlandes
Atopic Dermatitis
Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis
The purpose of this study is to evaluate the potential improvement in atopic dermatitis signs and symptoms following the application of FB-401 in patients 2 years or older with mild to moderate atopic dermatitis.
- Trial name
- NCT04504279
- Testing
- FB-401
- Where
- 15 sites in United States
- Volunteers
- 154 people
- Sponsor
- Forte Biosciences, Inc.
Atopic Dermatitis
Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis
Background: Atopic dermatitis (AD) is a skin disease also called eczema. It is common in children and sometimes gets better on its own. However, chronic AD may cause asthma, food allergies, eye infections, and sleep problems.
- Trial name
- NCT03018275
- Testing
- Roseomonas mucosa
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)